Allstate Corporation’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Allstate Corporation’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,542	Closed	-$217K	–	803
2021 Q4	$217K	Sell	4,542 -134	-3%	-$5.99K	﹤0.01%	739
2021 Q3	$311K	Buy	4,676 +1,220	+35%	+$86.9K	0.01%	626
2021 Q2	$270K	Buy	3,456 +856	+33%	+$63.3K	0.01%	670
2021 Q1	$246K	Sell	2,600 -9	-0.3%	-$1.07K	0.01%	686
2020 Q4	$318K	Sell	2,609 -416	-14%	-$45.6K	0.01%	605
2020 Q3	$264K	Sell	3,025 -648	-18%	-$45.1K	0.01%	597
2020 Q2	$237K	Buy	+3,673	New	+$212K	0.01%	632

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Allstate Corporation's TPTX Position: Q1 2022 in Review

Allstate Corporation sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 4,542 shares — an estimated $217K sold.

Allstate Corporation first reported a position in TPTX in Q2 2020 and held it in 7 quarters. The position peaked at $318K in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

Allstate Corporation reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Allstate Corporation sold 4,542 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $217K.
Allstate Corporation first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Allstate Corporation's Turning Point Therapeutics, Inc. Common Stock position peaked at $318K in Q4 2020.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Allstate Corporation's 13F filing for Q1 2022, filed 16 May 2022.